Hans Messner Allogeneic BMT Program

Official account of the Hans Messner Allogeneic Blood and Marrow Transplant Program at Princess Margaret Hospital, Toronto. Posts are not medical advice.

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Our multidisciplinary team endeavours to provide the highest standards of care. The overarching theme that drives our efforts are to get patients back to their normal lives by treating their diseases, limiting complications (NRM), and preserving quality of life (GRFS).

[Shernan Holtan MD @sghmd]

Swiss cheese 🧀 model of why PTCy + ATG may be complementary, not redundant. @nihardesai89 emphasized lower dose ATG is key. 🔑 @COSTEMCongress @Hans_BMTProgram

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Excellent presentation by Welaia Alsaffar (@welaia_ali): the “best donor” in allo-HCT is not defined by a fixed hierarchy. Disease, urgency and platform matter; HLA match and DSA remain central, with age, CMV status and availability refining the choice.

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Tomorrow at Monthly Fellows Rounds:

Guest speaker Welaia Alsaffar (@welaia_ali) presents:

“Who Is the Best Donor? Revisiting the Hierarchy of Donor Selection”

📅 Wed, Aug 26
🕛 12:00 pm
💻 MS Teams
@pmcancercentre @PMResearch_UHN

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Tomorrow morning at our Malignant Hematology Education Round:

🧬 Dr Dennis Kim: Post-EHA learnings
🎯 Mohamed Sharif, Clinical Fellow: “Remission Is Not the Finish Line”

Wed Aug 26 | 8:00-9:00 am
Hybrid: OPG + MS Teams

@pmcancercentre @PMResearch_UHN

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Tomorrow, Fri 21 Aug | Hans Messner Allogeneic BMT Academic Activity Rounds

🧬 Dr. Frank Michelis (@FotiosMichelis): second malignancies after allogeneic SCT

🚭 Dr. Ebaa Reda, Clinical Fellow: prior smoking history and post-allo-HCT outcomes

@pmcancercentre @PMResearch_UHN

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Invited attendees: please RSVP by Friday, 11 Sept to [email protected]

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

Invitation-only ⭐ Our 4th Annual Allogeneic BMT Patient Survivorship Day celebrates BMT survivors, their invited caregivers/family members and the BMT team.

📅 20 Sept 2026, 1–4 pm | Vaughan
📌Private event for invited attendees.

@pmcancercentre @UHN

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

📢 Now out in @BrJHaem 🎊🎉

Our latest work from the @pmcancercentre explores how GvHD prophylaxis influences the risk of second primary malignancies after allogeneic transplants using a large cohort of 1,418 patients (>6000 person-years of follow up)
https://t.co/wCsdX5WDzf

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

📢 Published in @ASTCT_Journal 🎉

Using a large dataset (@CIBMTR + @Hans_BMTProgram), we show that ATG + PTCy may alleviate the ⤴️GvHD risk associated with female donor-to-male recipient MUD transplants 🙌🏽
https://t.co/p9epD40RbD

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

🎉 Out now in @ASTCT_Journal 🙌🏽

We compare two conditioning regimens for second allogeneic transplant after primary graft failure!

Interesting results 👇🏽
DM me for the PDF!

https://t.co/5ESeV8lPwl @Hans_BMTProgram

[Ahmed AlNughmush @AhmedAlNughmush]

Our work is now out in @ASTCT_Journal

We looked into the association between cumulative cyclosporine exposure over the first 90 days (AUC90) post-HCT and key transplant outcomes, including graft failure and relapse.

@Hans_BMTProgram

https://t.co/hWEHnFM6fV

[Ruah Alyamany | روى اليماني @Ruah_Mahmoud]

Delighted to share our latest publication on the impact of conditioning intensity in younger AML patients receiving dual T-cell depletion for GVHD prophylaxis.
#Hematology #BMT

@AhmedAlNughmush @Hans_BMTProgram

https://t.co/ht6lNaMkmx

[Arjun D. Law @Haemophage]

Proud moment at the CTTC Conference!
Here’s a roundup of phenomenal poster presentations from our team at @Hans_BMTProgram @UHN and @pmcancercentre , tackling real-world challenges in transplant medicine and GVHD.
#CTTC2025 #HCT #GVHD #HemeTwitter
1/10

[Sergio Rodríguez-Rodriguez, MD, MSc. 🇲🇽 @SergioRdzRdz]

🚨 New Study Alert!
@nihardesai89 @Haemophage @IvanPasic

Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromes—a rare and challenging group of hematologic neoplasms. 🧵👇

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Excellent thread summarising key findings of our latest publication from @pmcancercentre 👇🏽

DM me if you want the PDF 🙌🏽

https://t.co/ryfscQagL2 #MedTwitter @SergioRdzRdz @Hans_BMTProgram @Haemophage

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

The abstract titles for #ASCO25 are out 🙌🏽

We asked 2 questions:
1. Can we ⤵️the PTCy dose in MUDs?

2. What's the outcome of patients who are alive 2 yr post transplant?

We'll answer those questions at the oral abstract session @ASCO

#MedTwitter @Hans_BMTProgram

[Hans Messner Allogeneic BMT Program @Hans_BMTProgram]

@pmcancercentre Thank you so much for your kind words! 💙
It is truly our privilege to be part of your journey and we’re grateful for the trust you placed in our team. Wishing you continued health and wellness!